Skip to content
Triangle logo TriangleGet started
← Study library

NCT01458288 · REGISTRY CONDITION SEARCH

A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2021-04-19

This Phase II study is to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 alone or in combination with G-CSF in Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg

→

outcome · POSTED

the Average Number of Leukapheresis Sessions

→

outcome · POSTED

Circulating CD34+ Cell Count in Peripheral Blood

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Male or female 18 to 75 years of age inclusive; * Patients with confirmed pathology diagnosis of MM, NHL or HD; * Potential candidate for autologous stem cell transplantation at Investigator's discretion; * 4 weeks since last cycle of chemotherapy prior to the study drug administration; * Total dose of melphalan received 200 mg in the most recent chemotherapy treatment; * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; * Recovered from all acute toxic effects of prior chemotherapy at Investigator's discretion; * White blood cell (WBC) count 3.0 x 109/L on screening laboratory assessments; * Absolute neutrophil count 1.5 x 109/L on screening laboratory assessments; * Platelet count 100 x 109/L on screening laboratory assessments; * Serum creatinine 2.2 mg/dL on screening laboratory assessments; * Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin \< 2 x upper limit of normal (ULN) on screening laboratory assessments; * Negative for human immunodeficiency virus (HIV); * Adequate cardiac and pulmonary function to undergo leukapheresis at Investigator's discretion; * For females, one of the following criteria must be fulfilled: 1. At least one year post-menopausal, or 2. Surgically sterile, or 3. Willing to use a double-barrier method \[intrauterine device (IUD) plus condom, spermicidal gel plus condom\] of contraception from study Day 1 until 28 days after the last dose of TG-0054; * Males must be willing to use a reliable form of contraception (use of a condom or a partner fulfilling the above criteria) from study Day 1 until 28 days after the last dose of TG-0054; * Able to provide the signed informed consent. Exclusion Criteria: * Received radiation therapy to the pelvis; * Received \> 6 cycles of lenalidomide; * Evidence of bone marrow involvement of lymphoma in NHL patients; * Failed previous stem cell collection \[failed to collect 2 x 106 CD34+ cells/kg within 4 leukapheresis sessions after receiving granulocyte colony-stimulating factor (G-CSF)\]; * Patients who have undergone previous stem cell transplantation procedure; * Received G-CSF within 2 weeks prior to the study drug administration; * History of other cancer within the past 5 years excluding MM, NHL, HD, basal cell or squamous cell carcinoma of the skin; * History of other hematologic disorders including bleeding or thromboembolic disease being treated with anti-coagulant; * History of poor and uncontrollable cardiovascular or pulmonary disease such as myocardial infarction, cardiac arrhythmias, transient ischemic attack, stroke or Chronic Obstructive Pulmonary Disease (COPD) patients hospitalized more than two times a year due to underlying disease; * Diagnosis of sickle cell anemia or documented sickle cell trait; * Patients with proliferative retinopathy; * Uncontrollable malignancy with MM, NHL or HD, or carcinomatous meningitis, at Investigator's discretion; * Any infection required antibiotic treatment or unexplained fever above 38 °C within 3 days prior to dosing; * Pregnant or breast-feeding; * Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study; * Received any other investigational drug within 1 month before entering the study; * Received prior treatment with TG-0054 but withdrew early from this study.
healthy Volunteers
false
maximum Age
75 Years
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    TG-0054 (3.14 mg/kg)
    intervention Names
    1. Drug: TG-0054
    label
    TG-0054 (3.14 mg/kg)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. TG-0054 (3.14 mg/kg)
    description
    3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions)
    name
    TG-0054
    other Names
    1. burixafor
    type
    DRUG
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
12
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Patients were all with multiple myeloma (MM), Non-Hodgkin lymphoma (NHL) or Hodgkin disease (HD). Number of patients who mobilized the targeted total number of CD34+ cells within a maximum of 4 leukapheresis sessions in study arm 1 and arm 3. Patients in arm 1 followed administration of TG-0054 (3.14 mg/kg) alone and leukapheresis start from study day 1. Patients in arm 3 followed administration of TG-0054 (3.14 mg/kg) combined with granulocyte colony-stimulating factor (G-CSF) and leukapheresis start from study day 8.
    measure
    Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg
    time Frame
    1 week
secondary Outcomes
  1. description
    To determine the average number of leukapheresis sessions required to collect 2.5 x10\^6 CD34+ cells/kg.
    measure
    the Average Number of Leukapheresis Sessions
    time Frame
    1 week
  2. description
    Calculate the median total CD34+ cell counts across all leukapheresis sessions following TG 0054 administration alone and in combination with G-CSF mobilization in order to evaluate the pharmacodynamics (PD) of TG-0054 by determining circulating CD34+ cell counts in peripheral blood.
    measure
    Circulating CD34+ Cell Count in Peripheral Blood
    time Frame
    pre-dose(-2 to 0 h),2, 4 and 6 hr after dosing.
Full study description
brief Summary
This Phase II study is to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 alone or in combination with G-CSF in Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease.
Source references
references
  1. citation
    Pan KS, Wang Z, Pfeil C, Bergkamp ND, Mobach S, Roth S, Rizk A, Lohse MJ, Annibale P, Siderius M, Zimmermann M, Smit MJ, Bosma R. Pharmacological characterization of a clinical candidate, TG-0054, a small molecule inverse agonist targeting CXCR4. Mol Pharmacol. 2025 Apr;107(4):100015. doi: 10.1016/j.molpha.2025.100015. Epub 2025 Jan 31.
    pmid
    40156952
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-ed0f7340fe7721110fdd
      requested nct id
      NCT01458288
      primary nct id
      NCT01458288
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      eb0d1670d9698834bb872a1afdc316a0caebb95d776908ffa7b47578f1cc8f42
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-ed0f7340fe7721110fdd
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01458288
      occurrences
      1. context exact
        NCT01458288
        end
        11
        exact text
        NCT01458288
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/80/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      158e0a9cc84393b22464ea65f8407d08cb0d4cd176bf1c2a7d390169ca35f7c0

    Preserved source evidence · Not medical advice